Moving from Minion to Manager

Image: Anne MacNamara Thomas Collett discovered a way to get the schooling he needed to become a biotechnology leader: He joined a company that paid for it. His postdoctoral training at the Scripps Research Institute in La Jolla, Calif., gave him entrance into McKinsey & Co, a worldwide management consultancy. As he traversed Germany on the firm's payroll, he developed the business networks and abilities to land an executive position at a startup company. Now, at only 38, he's a chief exec

Written byBob Calandra
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Thomas Collett discovered a way to get the schooling he needed to become a biotechnology leader: He joined a company that paid for it. His postdoctoral training at the Scripps Research Institute in La Jolla, Calif., gave him entrance into McKinsey & Co, a worldwide management consultancy. As he traversed Germany on the firm's payroll, he developed the business networks and abilities to land an executive position at a startup company. Now, at only 38, he's a chief executive officer (CEO).

For most postdoctoral trainees--those who don't land jobs at tony consultancies--the road out of the postdoc cell and into management may be littered with frustrations and false starts. Nevertheless, whether in academia or biotechnology, researchers can learn from Collett's experience by transforming every turn into a new lesson.

"You need to be lucky to have all the transitions work, and you have to be mentally prepared when the opportunities ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies